• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Hercules Capital Prices Upsized Institutional Notes Offering of $350.0 Million 6.000% Notes due 2030

    6/11/25 5:19:00 PM ET
    $HCXY
    $HTGC
    Investment Managers
    Finance
    Get the next $HCXY alert in real time by email

    Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), today announced that it has priced an upsized underwritten public offering of $350.0 million in aggregate principal amount of 6.000% notes due June 2030 (the "Notes"). The closing of the transaction is subject to customary closing conditions and the Notes are expected to be delivered and paid for on June 16, 2025.

    The Notes are unsecured and bear interest at a rate of 6.000% per year, payable semiannually and will mature on June 16, 2030 and may be redeemed in whole or in part at any time or from time to time at the Company's option at par, plus a "make whole" premium, if applicable.

    The Company expects to use the net proceeds from this offering to repay outstanding secured indebtedness under the Company's existing financing arrangements.

    Goldman Sachs & Co. LLC and SMBC Nikko Securities America, Inc. are acting as joint book-running managers of this offering. MUFG Securities Americas Inc., Zions Direct, Inc., RBC Capital Markets, LLC, Synovus Securities, Inc. and Keefe, Bruyette & Woods, A Stifel Company are acting as co-managers.

    The offering may be made only by means of a preliminary prospectus supplement and an accompanying prospectus. Copies of the preliminary prospectus supplement may be obtained from Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, New York 10282, or email: [email protected], or telephone: 1-866-471-2526, or SMBC Nikko Securities America, Inc., 277 Park Avenue, New York, New York 10172, Attention: Debt Capital Markets – Transaction Management, or email: [email protected], or telephone: 1-212-224-5135.

    Investors are advised to carefully consider the investment objectives, risks, charges and expenses of the Company before investing. The pricing term sheet dated June 11, 2025, the preliminary prospectus supplement dated June 11, 2025, and the accompanying prospectus dated December 11, 2024, each of which has been filed with the SEC, contain this and other information about the Company and should be read carefully before investing.

    The information in the pricing term sheet, the preliminary prospectus supplement, the accompanying prospectus and this press release is not complete and may be changed. The pricing term sheet, the preliminary prospectus supplement, the accompanying prospectus and this press release do not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the Notes in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

    About Hercules Capital, Inc.

    Hercules Capital, Inc. (NYSE:HTGC) is the leading and largest specialty finance company focused on providing senior secured venture growth loans to high-growth, innovative venture capital-backed companies in a broad variety of technology and life sciences industries. Since inception (December 2003), Hercules has committed more than $22 billion to over 680 companies and is the lender of choice for entrepreneurs and venture capital firms seeking growth capital financing. Companies interested in learning more about financing opportunities should contact [email protected], or call (650) 289-3060.

    Hercules, through its wholly owned subsidiary business, Hercules Adviser LLC (the "Adviser Subsidiary"), also maintains an asset management business through which it manages investments for external parties ("Adviser Funds"). The Adviser Subsidiary is registered as an investment adviser under the Investment Advisers Act of 1940.

    Hercules' common stock trades on the New York Stock Exchange (NYSE) under the ticker symbol "HTGC." In addition, Hercules has one retail bond issuance of 6.25% Notes due 2033 (NYSE:HCXY).

    Forward-Looking Statements

    This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. We may use words such as "anticipates," "believes," "expects," "intends," "will," "should," "may" and similar expressions to identify forward-looking statements. Forward-looking statements are not guarantees of future performance and should not be relied upon in making any investment decision. Such statements are based on currently available operating, financial and competitive information and are subject to various risks and uncertainties that could cause actual results to differ materially from our historical experience and our present expectations. While we cannot identify all such risks and uncertainties, we urge you to read the risks discussed in our Annual Report on Form 10-K and other materials that we publicly file with the Securities and Exchange Commission. Any forward-looking statements made in this press release are made only as of the date hereof. Hercules assumes no obligation to update any such statements in the future.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250611348578/en/

    Michael Hara

    Investor Relations and Corporate Communications

    Hercules Capital, Inc.

    (650) 433-5578

    [email protected]

    Get the next $HCXY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HCXY
    $HTGC

    CompanyDatePrice TargetRatingAnalyst
    Hercules Capital Inc.
    $HTGC
    12/12/2024$19.50 → $21.50Mkt Perform → Outperform
    Keefe Bruyette
    Hercules Capital Inc.
    $HTGC
    1/16/2024$17.00 → $17.50Buy → Neutral
    Compass Point
    Hercules Capital Inc.
    $HTGC
    11/21/2023$17.00Neutral
    UBS
    Hercules Capital Inc.
    $HTGC
    8/30/2023$17.50Neutral → Buy
    Compass Point
    Hercules Capital Inc.
    $HTGC
    8/4/2023$13.50 → $17.00Underperform → Mkt Perform
    Keefe Bruyette
    Hercules Capital Inc.
    $HTGC
    4/6/2023$16.00Neutral → Overweight
    Piper Sandler
    Hercules Capital Inc.
    $HTGC
    3/13/2023$14.50 → $10.50Mkt Perform → Underperform
    Keefe Bruyette
    Hercules Capital Inc.
    $HTGC
    7/29/2022Outperform → Perform
    Oppenheimer
    More analyst ratings

    $HCXY
    $HTGC
    SEC Filings

    See more
    • SEC Form FWP filed by Hercules Capital Inc.

      FWP - Hercules Capital, Inc. (0001280784) (Subject)

      6/11/25 5:22:13 PM ET
      $HTGC
      Investment Managers
      Finance
    • SEC Form 497AD filed by Hercules Capital Inc.

      497AD - Hercules Capital, Inc. (0001280784) (Filer)

      6/11/25 5:16:36 PM ET
      $HTGC
      Investment Managers
      Finance
    • SEC Form 497AD filed by Hercules Capital Inc.

      497AD - Hercules Capital, Inc. (0001280784) (Filer)

      6/10/25 4:54:50 PM ET
      $HTGC
      Investment Managers
      Finance

    $HCXY
    $HTGC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Follmann Christian sold $7,043 worth of shares (395 units at $17.83) and bought $7,043 worth of shares (395 units at $17.83), increasing direct ownership by 0.22% to 121,212 units (SEC Form 4)

      4 - Hercules Capital, Inc. (0001280784) (Issuer)

      6/5/25 6:38:34 PM ET
      $HTGC
      Investment Managers
      Finance
    • Director Theodosopoulos Nikos bought $104,923 worth of shares (5,999 units at $17.49), increasing direct ownership by 101% to 11,960 units (SEC Form 4)

      4 - Hercules Capital, Inc. (0001280784) (Issuer)

      5/9/25 4:22:23 PM ET
      $HTGC
      Investment Managers
      Finance
    • Director Loo Wade bought $104,923 worth of shares (5,999 units at $17.49), returned 5,645 shares to the company and was granted 5,645 shares, increasing direct ownership by 5% to 7,504 units (SEC Form 4)

      4 - Hercules Capital, Inc. (0001280784) (Issuer)

      5/9/25 4:22:04 PM ET
      $HTGC
      Investment Managers
      Finance

    $HCXY
    $HTGC
    Leadership Updates

    Live Leadership Updates

    See more

    $HCXY
    $HTGC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Revelation Partners Expands Team with Hire of Andrew Olson, Partner, Chief Financial Officer & Chief Operating Officer

      SAUSALITO, Calif., Nov. 29, 2023 /PRNewswire/ -- Revelation Partners, a healthcare investment firm with over $1.5 billion of capital under management, announced today the addition of Andrew Olson as Partner, Chief Financial Officer and Chief Operating Officer. Mr. Olson has an extensive background in the venture capital and funds management industry. His addition to the team will enhance the firm's technical expertise, support the differentiated investment model, and strengthen the firm's ongoing foundation. As the firm's new Chief Financial Officer and Chief Operating Officer

      11/29/23 1:01:00 PM ET
      $HTGC
      $TPVG
      Investment Managers
      Finance
      Other Consumer Services
      Consumer Discretionary
    • Hercules Capital Announces the Appointment of Mr. Nikos Theodosopoulos to Its Board of Directors

      Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Nikos Theodosopoulos was appointed to serve as an independent member of its board of directors, effective September 21, 2023. Mr. Theodosopoulos is an experienced corporate executive and board director with more than 38 years in senior management roles in both the financial services and technology industries. Mr. Theodosopoulos will serve on the Company's Audit Committee. "Nikos' combined experienc

      9/25/23 6:00:00 AM ET
      $HCXY
      $HTGC
      Investment Managers
      Finance
    • Hercules Capital Announces the Appointment of Ms. DeAnne Aguirre to Its Board of Directors

      Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that DeAnne Aguirre was appointed to serve as an independent member of its board of directors, effective June 23, 2022. Ms. Aguirre is an experienced corporate executive and Board Director with more than 30 years in senior leadership managing large and complex domestic and international business units. Ms. Aguirre will serve on the Nominating and Corporate Governance Committee. "As we continue to expand o

      6/24/22 6:00:00 AM ET
      $HCXY
      $HTGC
      Investment Managers
      Finance
    • Hercules Capital Renews and Increases Its Credit Facility with MUFG Bank, Ltd. to $440.0 Million

      Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty finance provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has upsized and renewed its existing $400.0 million credit facility with MUFG Bank, Ltd. ("MUFG") with an upsized credit facility under which Goldman Sachs Bank USA, Autobahn Funding Company LLC, City National Bank, a National Banking Association, Umpqua Bank, Valley National Bank, Citizens Bank, N.A., Zions Bancorporation, N.A., dba California Bank & Trust and Mitsubishi HC Capital America, Inc. toge

      6/12/25 4:04:00 PM ET
      $HCXY
      $HTGC
      Investment Managers
      Finance
    • Hercules Capital Prices Upsized Institutional Notes Offering of $350.0 Million 6.000% Notes due 2030

      Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), today announced that it has priced an upsized underwritten public offering of $350.0 million in aggregate principal amount of 6.000% notes due June 2030 (the "Notes"). The closing of the transaction is subject to customary closing conditions and the Notes are expected to be delivered and paid for on June 16, 2025. The Notes are unsecured and bear interest at a rate of 6.000% per year, payable semiannually and will mature on June 16, 2030 and may be redeemed in whole or in part at any time or from time to time at the Company's option at par, plus a "make whole" premium, if applicable. The Company expects to use the net pro

      6/11/25 5:19:00 PM ET
      $HCXY
      $HTGC
      Investment Managers
      Finance
    • Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital

      GAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has entered into an agreement with Hercules Capital, Inc. (NYSE:HTGC), a leader in debt financing for life science companies, for up to $100 million in a credit facility, with a $15 million tranche funded at closing. Additional tranches will become available upon achievement of certain clinical and financial milestones aligned with the Company's pemvidutide development plans and financing needs. Access to this additional capital strengthens Altimmune's ba

      5/13/25 7:00:00 AM ET
      $ALT
      $HTGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Investment Managers
      Finance

    $HCXY
    $HTGC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Hercules Capital Inc.

      SC 13G - Hercules Capital, Inc. (0001280784) (Subject)

      5/8/23 5:06:26 PM ET
      $HTGC
      Investment Managers
      Finance
    • SEC Form SC 13G/A filed by Hercules Capital Inc. (Amendment)

      SC 13G/A - Hercules Capital, Inc. (0001280784) (Filed by)

      10/12/22 9:11:00 AM ET
      $HTGC
      Investment Managers
      Finance
    • SEC Form SC 13G filed by Hercules Capital Inc.

      SC 13G - Hercules Capital, Inc. (0001280784) (Filed by)

      4/27/22 4:31:08 PM ET
      $HTGC
      Investment Managers
      Finance

    $HCXY
    $HTGC
    Financials

    Live finance-specific insights

    See more
    • MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

      MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update Continued to make significant progress with the development of the Nanobody® sonelokimab across portfolio of indications, including Phase 3 studies in hidradenitis suppurativa (HS), psoriatic Arthritis (PsA) and adolescent HS, as well as Phase 2 studies in palmoplantar pustulosis (PPP) and axial spondyloarthritis (axSpA)Announced completion of enrollment of patients in the Phase 3 program in HS (the VELA program) and disclosed baseline characteristics, replicating the Phase 2 MIRA trialPresented an interim readout of the Phase 2 LEDA study in PPP, highlighting the potential of sonelokimab

      5/12/25 4:00:00 PM ET
      $HTGC
      $MLTX
      Investment Managers
      Finance
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hercules Capital Announces Date of 2025 Annual Meeting of Stockholders

      Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), will conduct its 2025 Annual Meeting of Stockholders by virtual meeting on Wednesday, June 18, 2025 at 9:00 a.m. (Eastern Time). The proxy statement for the meeting was filed on April 24, 2025 and mailed to stockholders of record as of April 17, 2025. 2025 Annual Meeting of Stockholders June 18, 2025 at 9:00 a.m. Eastern Time Virtual Meeting via Internet: http://www.virtualshareholdermeeting.com/HTGC2025 Matters to be voted on include: 1) election of three directors, 2) an advisory vote on the compensation of the Company's named executive officers, 3) authorization of the Company to sell or issue shares of its common stock

      5/8/25 6:00:00 AM ET
      $HCXY
      $HTGC
      Investment Managers
      Finance
    • Hercules Capital Reports First Quarter 2025 Financial Results

      Q1 2025 Total Gross Debt and Equity Commitments of $1.02 Billion Q1 2025 Total Gross Fundings of $539.1 Million Q1 2025 Total Investment Income of $119.5 Million Q1 2025 Net Investment Income "NII" of $77.5 Million, or $0.45 per Share Q1 2025 NII of $0.45 per Share, provides 113% Coverage of the Base Cash Distribution Received an Investment Grade Rating Upgrade to BBB (high) from Morningstar DBRS Closed Offering of $287.5 Million of 4.750% Convertible Unsecured Notes due 2028 Conservative Balance Sheet Management with Net GAAP Leverage of 97.4% and Net Regulatory Leverage of 82.7%(1) Inclusive of the Adviser Funds Advised by Hercules Adviser LLC, its Wholly-Owned Subsidiary, Hercule

      5/1/25 4:04:00 PM ET
      $HCXY
      $HTGC
      Investment Managers
      Finance

    $HCXY
    $HTGC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Hercules Capital upgraded by Keefe Bruyette with a new price target

      Keefe Bruyette upgraded Hercules Capital from Mkt Perform to Outperform and set a new price target of $21.50 from $19.50 previously

      12/12/24 8:09:58 AM ET
      $HTGC
      Investment Managers
      Finance
    • Hercules Capital downgraded by Compass Point with a new price target

      Compass Point downgraded Hercules Capital from Buy to Neutral and set a new price target of $17.50 from $17.00 previously

      1/16/24 8:29:29 AM ET
      $HTGC
      Investment Managers
      Finance
    • UBS initiated coverage on Hercules Capital with a new price target

      UBS initiated coverage of Hercules Capital with a rating of Neutral and set a new price target of $17.00

      11/21/23 7:31:43 AM ET
      $HTGC
      Investment Managers
      Finance

    $HCXY
    $HTGC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Follmann Christian sold $7,043 worth of shares (395 units at $17.83) and bought $7,043 worth of shares (395 units at $17.83), increasing direct ownership by 0.22% to 121,212 units (SEC Form 4)

      4 - Hercules Capital, Inc. (0001280784) (Issuer)

      6/5/25 6:38:34 PM ET
      $HTGC
      Investment Managers
      Finance
    • Director Theodosopoulos Nikos bought $104,923 worth of shares (5,999 units at $17.49), increasing direct ownership by 101% to 11,960 units (SEC Form 4)

      4 - Hercules Capital, Inc. (0001280784) (Issuer)

      5/9/25 4:22:23 PM ET
      $HTGC
      Investment Managers
      Finance
    • Director Loo Wade bought $104,923 worth of shares (5,999 units at $17.49), returned 5,645 shares to the company and was granted 5,645 shares, increasing direct ownership by 5% to 7,504 units (SEC Form 4)

      4 - Hercules Capital, Inc. (0001280784) (Issuer)

      5/9/25 4:22:04 PM ET
      $HTGC
      Investment Managers
      Finance